摘要
目的:对地氯雷他定与依匹斯汀对慢性荨麻疹的治疗成本以及效果进行对比。方法:选取180例慢性荨麻疹患者为研究对象,随机分为观察组与对照组,观察组90例,选用地氯雷他定治疗,对照组90例,选用依匹斯汀治疗。对两组患者的治疗有效率、不良反应发生率以及治疗成本进行对比。结果:观察组与对照组患者的治疗总有效率比较,差异无统计学意义(χ~2=0.117,P>0.05);两组患者的不良反应发生率比较,差异无统计学意义(χ~2=0.117,P>0.05);比较两组的成本效果比,观察组低于对照组(χ~2=6.352,P=0.035)。结论:采用地氯雷他定与依匹斯汀治疗慢性荨麻疹,临床效果与不良反应发生率相近,而地氯雷他定取得单位治疗效果所需成本相对较低,更具有经济学价值。
Objective：To compare the clinical cost and effect of desloratadine and epinastine in the treatment of chronic urticaria. Methods： 180 cases of patients with chronic urticaria were divided into observation group and control group, 90 cases in each group. The patients in observation group were treated with desloratadine and those in control group were treated with epinastine. The therapeutic effect, incidence of adverse reactions and treatment cost in the two groups were compared and analyzed. Results： There was no significant difference in the effective rate of treatment （X2 = 0.117, P 〉 0.05） and incidence of adverse reactions （x^2 = 0.117, P 〉 0.05 ） between the two groups. The cost - effectiveness ratio in observation group was lower than that in control group （ x^2 = 6. 352, P = 0.035）. Conclusion： The use of desloratadine and epinastine in the treatment of chronic urticaria has little difference in clinical effect and the incidence of adverse reactions. Desloratadine has relatively more economic value with lower clinical cost.
出处
《包头医学院学报》
CAS
2017年第4期42-43,共2页
Journal of Baotou Medical College
